McIlrath & Eck’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $786K | Buy |
855
+236
| +38% | +$239K | 0.06% | 109 |
|
|
2025
Q4 | $666K | Sell |
619
-110
| -15% | -$105K | 0.06% | 77 |
|
|
2025
Q3 | $556K | Buy |
729
+80
| +12% | +$59.5K | 0.06% | 79 |
|
|
2025
Q2 | $506K | Sell |
649
-73
| -10% | -$56.7K | 0.06% | 78 |
|
|
2025
Q1 | $597K | Buy |
722
+101
| +16% | +$84K | 0.07% | 70 |
|
|
2024
Q4 | $479K | Buy |
621
+140
| +29% | +$116K | 0.06% | 78 |
|
|
2024
Q3 | $426K | Buy |
481
+16
| +3% | +$14.4K | 0.05% | 84 |
|
|
2024
Q2 | $421K | Hold |
465
| – | – | 0.06% | 76 |
|
|
2024
Q1 | $362K | Hold |
465
| – | – | 0.06% | 84 |
|
|
2023
Q4 | $271K | Buy |
465
+66
| +17% | +$38.5K | 0.05% | 99 |
|
|
2023
Q3 | $215K | Buy |
399
+31
| +8% | +$16K | 0.04% | 113 |
|
|
2023
Q2 | $173K | Sell |
368
-3
| -0.8% | -$1.26K | 0.04% | 118 |
|
|
2023
Q1 | $127K | Buy |
371
+3
| +0.8% | +$1.01K | 0.03% | 135 |
|
|
2022
Q4 | $135K | Buy |
368
+10
| +3% | +$3.55K | 0.03% | 126 |
|
|
2022
Q3 | $116K | Buy |
358
+200
| +127% | +$63.4K | 0.03% | 131 |
|
|
2022
Q2 | $51K | Hold |
158
| – | – | 0.02% | 231 |
|
|
2022
Q1 | $45K | Sell |
158
-1
| -0.6% | -$257 | 0.01% | 257 |
|
|
2021
Q4 | $44K | Hold |
159
| – | – | 0.01% | 258 |
|
|
2021
Q3 | $37K | Hold |
159
| – | – | 0.01% | 279 |
|
|
2021
Q2 | $36K | Hold |
159
| – | – | 0.01% | 280 |
|
|
2021
Q1 | $30K | Hold |
159
| – | – | 0.01% | 272 |
|
|
2020
Q4 | $27K | Hold |
159
| – | – | 0.01% | 257 |
|
|
2020
Q3 | $24K | Hold |
159
| – | – | 0.01% | 231 |
|
|
2020
Q2 | $26K | Buy |
159
+22
| +16% | +$3.38K | 0.01% | 202 |
|
|
2020
Q1 | $19K | Hold |
137
| – | – | 0.01% | 199 |
|
|
2019
Q4 | $18K | Hold |
137
| – | – | 0.01% | 258 |
|
|
2019
Q3 | $15K | Hold |
137
| – | – | 0.01% | 270 |
|
|
2019
Q2 | $18K | Hold |
137
| – | – | 0.01% | 213 |
|
|
2019
Q1 | $18K | Hold |
137
| – | – | 0.01% | 213 |
|
|
2018
Q4 | $16K | Hold |
137
| – | – | 0.01% | 218 |
|
|
2018
Q3 | $15K | Hold |
137
| – | – | 0.01% | 244 |
|
|
2018
Q2 | $12K | Buy |
137
+37
| +37% | +$3.04K | 0.01% | 253 |
|
|
2018
Q1 | $8K | Hold |
100
| – | – | ﹤0.01% | 291 |
|
|
2017
Q4 | $8K | Buy |
+100
| New | +$8.51K | ﹤0.01% | 305 |
|
Other funds holding LLY
McIlrath & Eck's LLY Position: Q1 2026 in Review
McIlrath & Eck increased its Eli Lilly (LLY) stake by 38% in Q1 2026, buying an estimated $239K and bringing the position to 855 shares worth $786K. The position accounts for 0.06% of the portfolio, ranked #109.
McIlrath & Eck first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. 4,379 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- McIlrath & Eck held 855 shares of Eli Lilly worth $786K as of Q1 2026.
- McIlrath & Eck bought 236 Eli Lilly shares in Q1 2026, an estimated $239K.
- Eli Lilly made up 0.06% of McIlrath & Eck's portfolio in Q1 2026, its #109 holding.
- McIlrath & Eck first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- 4,379 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.